NCT01548911 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (NCT01548911)

Trial Description
This clinical trial studies the side effects of the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) and how well it works in treating patients with acute myeloid leukemia. Monoclonal antibodies, including the antibody-drug conjugate gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

This trial is sponsored by the Comprehensive Cancer Center at Wake Forest University / National Cancer Institute (NCI). [1]

Study Data

  • Condition:
    • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
    • Adult Acute Myeloid Leukemia With Del(5q)
    • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
    • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
    • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
    • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
    • Adult Acute Promyelocytic Leukemia (M3)
    • Recurrent Adult Acute Myeloid Leukemia
  • Interventions:
  • Phase: 0
  • Enrollment: 0
  • Start: May 2012
  • Estimated Primary Completion: March 2018
  • Last verified: September 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 20, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.